National Institute of Neurological Disorders and Stroke
6001 Executive Blvd Rm. 3221A
6 articles with National Institute of Neurological Disorders and Stroke
CND Life Sciences Awarded NIH SBIR Grant to Advance Diagnostic Technology for Neurodegenerative Diseases
Grant Supports the Continued Validation and Enhancement of the Syn-One Test™ To Help Physicians Diagnose Parkinson's Disease and Other Serious Disorders
This Grant will Enable to Company to Complete its Pre-Clinical Research and Make Key Preparations to Start a Clinical Trial
ARMGO® Pharma Inc. Announces Clinical Trial of ARM210/S48168 for the Treatment of Ryanodine Receptor Type 1 Related Myopathies
In 2018, the FDA granted orphan drug designation to ARMGO for ARM210 as a potential treatment for patients with RYR1-RM.
PsychoGenics Awarded NIH HEAL Initiative Contract for Preclinical Screening Platform for Pain (PSPP)
Platform Available to Research Community to Profile Novel Nonaddictive Analgesic Treatments
AcuraStem Triggers $3M Phase II Fast Track SBIR Grant to Accelerate Preclinical Development of its AS-1 Program for ALS
MONROVIA, Calif., October 22, 2019 – AcuraStem, a biotechnology company advancing neuroscience through patient-based drug discovery, announced today that the company has triggered Phase II funding worth $3 million from its Fast Track Small Business Innovation Research grant awarded by the National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health *[Award Number R44NS105156].
Expesicor announced that the National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health, has awarded the company $343,042 over one year for the first phase of a Small Business Innovation Research grant award.